Date: October 06, 2023
Elizabeth Brem, MD, began her talk by addressing some disclosures she had omitted in her previous presentation. She then stressed the importance of intergroup studies, particularly for rare populations like PTCL and HL. She highlighted their unique ability to establish real comparator arms, citing examples from CLL trials.
Moving on to specific studies, Dr. Brem emphasized the groundbreaking nature of “eighteen twenty six” in Hodgkin lymphoma, describing it as a study poised to change the standard of care in a way that no other mechanism could achieve. She also discussed the potential of large datasets, which could still influence standard care even if the therapeutic endpoint wasn’t met.
Dr. Brem touched on various ongoing studies, including “dramatic,” “EA forty one, fifty one,” and “nineteen eighteen,” stressing their significance in the field.
The central focus of her presentation was the study “eighteen twenty six” in Hodgkin lymphoma. She presented data indicating an improvement in the one-year PFS in the Nivo ABD arm compared to BB ABD. Dr. Brem underlined the study’s potential to set a new standard of care, adding that it could not have been conducted through any other mechanism.
She concluded by emphasizing the importance of teamwork and collaboration in intergroup studies, especially in the complex realm of Early stage Hodgkin’s lymphoma designs. Dr. Brem’s presentation left the audience with a deep appreciation for the value of intergroup studies in advancing cancer research.